Sonal Gupta

Dr. Sonal Gupta

The UT MD Anderson Cancer Center
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
VCVidhi Chandra
Vidhi Chandra
ESErick Riquelme Sanchez
Erick Riquelme Sanchez
PDPrasanta Dutta
Prasanta Dutta
PQPompeyo R. Quesada
Pompeyo R. Quesada
FMFlorencia McAllister
Florencia McAllister
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal malignancy with an immunosuppressive microenvironment that is resistant to most therapies. IL17 is involved in pancreatic tumorigenesis, but its role in invasive PDAC is undetermined. We hypothesized that IL17 triggers and sustains PDAC immunosuppression. We inhibited IL17/IL17RA signaling using pharmacological and genetic strategies alongside mass cytometry and multiplex immunofluorescence techniques. We uncovered that IL17 recruits neutrophils, triggers neutrophil extracellular traps (NETs), and excludes cytotoxic CD8 T cells from tumors. Additionally, IL17 blockade increases immune checkpoint blockade (PD-1, CTLA4) sensitivity. Inhibition of neutrophils or Padi4-dependent NETosis phenocopies IL17 neutralization. NMR spectroscopy revealed changes in tumor lactate as a potential early biomarker for IL17/PD-1 combination efficacy. Higher expression of IL17 and PADI4 in human PDAC corresponds with poorer prognosis, and the serum of patients with PDAC has higher potential for NETosis. Clinical studies with IL17 and checkpoint blockade represent a novel combinatorial therapy with potential efficacy for this lethal disease.

22 August 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
MYMeifang Yu
Meifang Yu
NNNicholas Nguyen
Nicholas Nguyen
YHYanqing Huang
Yanqing Huang
Daniel LinDaniel Lin
Daniel Lin
TFTara N. Fujimoto
Tara N. Fujimoto
Cullen M. TaniguchiCullen M. Taniguchi
Cullen M. Taniguchi
Pancreatic ductal adenocarcinoma (PDAC) requires mitochondrial oxidative phosphorylation (OXPHOS) to fuel its growth; however, broadly inhibiting this pathway might also disrupt essential mitochondrial functions in normal tissues. PDAC cells exhibit abnormally fragmented mitochondria that are essential to the oncogenicity of PDAC, but it was unclear if this mitochondrial feature was a valid therapeutic target. Here, we present evidence that normalizing the fragmented mitochondria of pancreatic cancer via the process of mitochondrial fusion reduces OXPHOS, which correlates with suppressed tumor growth and improved survival in preclinical models. Mitochondrial fusion was achieved by genetic or pharmacologic inhibition of dynamin-related protein-1 (Drp1) or through overexpression of mitofusin-2 (Mfn2). Notably, we found that oral leflunomide, an FDA-approved arthritis drug, promoted a 2-fold increase in Mfn2 expression in tumors and was repurposed as a chemotherapeutic agent, improving the median survival of mice with spontaneous tumors by 50% compared with vehicle. We found that the chief tumor-suppressive mechanism of mitochondrial fusion was enhanced mitophagy, which proportionally reduced mitochondrial mass and ATP production. These data suggest that mitochondrial fusion is a specific and druggable regulator of pancreatic cancer growth that could be rapidly translated to the clinic.

1 July 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YZYu Zhang
Yu Zhang
MZMichelle Zoltan
Michelle Zoltan
ERErick Riquelme
Erick Riquelme
HXHanwen Xu
Hanwen Xu
ISIsmet Sahin
Ismet Sahin
FMFlorencia McAllister
Florencia McAllister

1 December 2008 in Molecular Immunology
Verified
Journal Article
Closed access
SGSonal Gupta
Sonal Gupta
SMSanthakumar Manicassamy
Santhakumar Manicassamy
CVChenthamarakshan Vasu
Chenthamarakshan Vasu
AKAnvita Kumar
Anvita Kumar
WSWeirong Shang
Weirong Shang
ZSZuoming Sun
Zuoming Sun

1 November 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
NINoboru Ideno
Noboru Ideno
HYHiroshi Yamaguchi
Hiroshi Yamaguchi
BGBidyut Ghosh
Bidyut Ghosh
SGSonal Gupta
Sonal Gupta
TOTakashi Okumura
Takashi Okumura
AMAnirban Maitra
Anirban Maitra

30 June 2012 in Oncotarget
Verified
Journal Article
Open access
PDF file
DPDipankar Pramanik
Dipankar Pramanik
NCNathaniel R. Campbell
Nathaniel R. Campbell
SDSamarjit Das
Samarjit Das
SGSonal Gupta
Sonal Gupta
VCVenugopal Chenna
Venugopal Chenna
AMAnirban Maitra
Anirban Maitra
A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy